Free Trial

Qiagen (NYSE:QGEN) Given New $55.00 Price Target at JPMorgan Chase & Co.

Qiagen logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • JPMorgan raised Qiagen’s price target from $50 to $55 and maintained an “overweight” rating, implying approximately 20.77% upside from the stock’s reported price of $45.54.
  • Qiagen’s latest quarterly results exceeded expectations, with EPS of $0.62 versus the $0.60 consensus and revenue of $535.04 million versus estimates of $527.50 million.
  • Analyst sentiment remains mixed: Qiagen has an average “Hold” rating and a consensus price target of $43.93, while institutional investors own about 70% of the company’s shares.
  • Interested in Qiagen? Here are five stocks we like better.

Qiagen (NYSE:QGEN - Get Free Report) had its price target upped by equities research analysts at JPMorgan Chase & Co. from $50.00 to $55.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective indicates a potential upside of 20.77% from the company's current price.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings upgraded shares of Qiagen from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, September 11th. Kepler Capital Markets set a $38.60 price target on shares of Qiagen and gave the company a "hold" rating in a research report on Thursday, June 25th. Barclays set a $40.00 price objective on shares of Qiagen and gave the stock an "equal weight" rating in a research report on Friday, August 7th. Citigroup reissued a "neutral" rating and issued a $45.00 price objective (up from $38.00) on shares of Qiagen in a report on Monday, August 10th. Finally, Berenberg Bank set a $45.50 price target on shares of Qiagen and gave the stock a "hold" rating in a report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Qiagen currently has an average rating of "Hold" and a consensus price target of $43.93.

View Our Latest Analysis on QGEN

Qiagen Stock Performance

NYSE QGEN traded up $0.10 during trading hours on Wednesday, reaching $45.54. The stock had a trading volume of 1,632,435 shares, compared to its average volume of 2,464,141. Qiagen has a 52-week low of $32.53 and a 52-week high of $57.81. The stock has a fifty day moving average of $43.59 and a 200 day moving average of $40.20. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85. The stock has a market cap of $9.38 billion, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 4.51 and a beta of 0.61.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.60 by $0.02. The company had revenue of $535.04 million during the quarter, compared to analyst estimates of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. Qiagen's revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the firm posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. Sell-side analysts predict that Qiagen will post 2.43 earnings per share for the current year.

Hedge Funds Weigh In On Qiagen

A number of institutional investors have recently added to or reduced their stakes in QGEN. GAMMA Investing LLC acquired a new position in shares of Qiagen during the 3rd quarter valued at about $345,000. State Street Corp increased its position in Qiagen by 4.5% during the second quarter. State Street Corp now owns 2,183,206 shares of the company's stock worth $85,363,000 after purchasing an additional 93,575 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new stake in Qiagen during the second quarter worth about $252,000. WINTON GROUP Ltd acquired a new stake in Qiagen during the second quarter worth about $1,423,000. Finally, Engineers Gate Manager LP increased its position in Qiagen by 107.7% during the second quarter. Engineers Gate Manager LP now owns 74,567 shares of the company's stock worth $2,916,000 after purchasing an additional 38,658 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company's stock.

About Qiagen

(Get Free Report)

QIAGEN N.V. NYSE: QGEN is a global provider of sample technologies, molecular testing solutions and bioinformatics products. The company develops tools that help researchers and healthcare professionals isolate, analyze and interpret biological materials, including DNA, RNA and proteins.

Its portfolio includes laboratory kits and instruments for sample preparation, polymerase chain reaction (PCR), next-generation sequencing, genotyping and molecular diagnostics. QIAGEN also provides digital and bioinformatics solutions used to manage and analyze biological data.

See Also

Analyst Recommendations for Qiagen (NYSE:QGEN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Qiagen Right Now?

Before you consider Qiagen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.

While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines